Alpha Mangostin Ameliorates Gestational Diabetes in Rats via Alteration of Oxidative Stress and Inflammation Reaction

Background and Objective: Diabetes mellitus and impaired glucose tolerance discovered during pregnancy without a previous history of the disease are referred to as Gestational Diabetes Mellitus (GDM).GDM is known to have a high chance of causing type 2 diabetes.GDM is becoming more common around the world and it has a significant impact on patientʼs quality of life and raises the risk of pregnancy.The current study scrutinized the protective effect of alpha mangostin against streptozotocin (STZ) induced Gestational Diabetes Mellitus (GDM) in rats.Materials and Methods: Wistar rats were used in this experimental study.The STZ was used for the induction of GDM.The rats received the oral administration of alpha mangostin (5, 10 and 15 mg kgG 1 ).Blood glucose level, fetal weight, body weight, placental weight and plasma insulin were estimated.Intraperitoneal Insulin Tolerance Test ( IpITT) and Oral Glucose Tolerance Test (OGTT) were determined.The mRNA expression of SREBP-1 and its targeted genes.Results: Alpha mangostin significantly (p<0.001)improved the plasma insulin level and body weight and reduced blood glucose level.Alpha mangostin significantly (p<0.001)improved the insulin level in IPTT and reduced the blood glucose level in the OGTT test.Alpha mangostin treatment considerably improved fetal weight and suppressed placental weight.Alpha mangostin significantly (p<0.001)altered the lipid, antioxidant and inflammatory cytokines.Alpha mangostin significantly (p<0.001)suppressed the mRNA expression of SCD-1, SREBP-1, FAS and ACC.Conclusion: Taken together, alpha mangostin can be considered an alternative treatment for gestational diabetes.